Patents by Inventor Donna Cabral-Lilly
Donna Cabral-Lilly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230172855Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.Type: ApplicationFiled: July 13, 2022Publication date: June 8, 2023Applicant: Celalor Pharmaceuticals, Inc.Inventors: Donna CABRAL-LILLY, Lawrence MAYER, Paul TARDI, David WATKINS, Yi ZENG
-
Publication number: 20210169803Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.Type: ApplicationFiled: November 13, 2020Publication date: June 10, 2021Applicant: Celator Pharmaceuticals, Inc.Inventors: Donna CABRAL-LILLY, Lawrence MAYER, Paul TARDI, David WATKINS, Yi ZENG
-
Patent number: 10835492Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.Type: GrantFiled: November 5, 2018Date of Patent: November 17, 2020Assignee: CELATOR PHARMACEUTICALS, INC.Inventors: Donna Cabral-Lilly, Lawrence Mayer, Paul Tardi, David Watkins, Yi Zeng
-
Publication number: 20190070112Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.Type: ApplicationFiled: November 5, 2018Publication date: March 7, 2019Applicant: CELATOR PHARMACEUTICALS INC.Inventors: Donna CABRAL-LILLY, Lawrence MAYER, Paul TARDI, David WATKINS, Yi ZENG
-
Patent number: 10166184Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.Type: GrantFiled: February 7, 2018Date of Patent: January 1, 2019Assignee: CELATOR PHARMACEUTICALS INC.Inventors: Donna Cabral-Lilly, Lawrence Mayer, Paul Tardi, David Watkins, Yi Zeng
-
Patent number: 10028912Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.Type: GrantFiled: October 15, 2012Date of Patent: July 24, 2018Assignee: CELATOR PHARMACEUTICALS, INC.Inventors: Donna Cabral-Lilly, Lawrence Mayer, Paul Tardi, David Watkins, Yi Zeng
-
Publication number: 20180161273Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.Type: ApplicationFiled: February 7, 2018Publication date: June 14, 2018Applicant: CELATOR PHARMACEUTICALS INC.Inventors: Donna CABRAL-LILLY, Lawrence MAYER, Paul TARDI, David WATKINS, Yi ZENG
-
Publication number: 20140255475Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.Type: ApplicationFiled: October 15, 2012Publication date: September 11, 2014Inventors: Donna Cabral-Lilly, Lawrence Mayer, Paul Tardi, David Watkins, Yi Zeng
-
Publication number: 20090098196Abstract: The invention relates to a method for reducing the polydispersity of a population of gel-phase lipid-based delivery vehicles.Type: ApplicationFiled: January 26, 2006Publication date: April 16, 2009Inventors: Paul Tardi, Lawrence Mayer, Donna Cabral-Lilly
-
Publication number: 20090068256Abstract: This invention provides a method to prepare liposome-encapsulated bioactive agents, such as nucleic acids, comprising complexation of the bioactive agents to reverse micelles prior to forming liposomes, as well as methods of using the liposomes so formed and formulations to deliver nucleic acids to cells.Type: ApplicationFiled: August 25, 2008Publication date: March 12, 2009Inventors: Paul Meers, Tong Shangguan, Donna Cabral-Lilly, Andrew Janoff, Patrick Ahl
-
Patent number: 7491409Abstract: This invention provides a method to prepare liposome-encapsulated bioactive agents such as nucleic acids, comprising complexation of the bioactive agents in reverse micelles prior to forming liposomes, as well as methods of using the liposomes so formed and formulations to deliver nucleic acids to cells.Type: GrantFiled: March 1, 2000Date of Patent: February 17, 2009Assignee: Transave, Inc.Inventors: Paul R. Meers, Tong Shangguan, Donna Cabral-Lilly, Patrick Ahl, Andrew S. Janoff
-
Publication number: 20060172003Abstract: A liposome including a fusogenic liposome, a linking moiety and a targeting moiety. The fusogenic liposome is a lipid bilayer encapsulating contents. The linking moiety is electrostatically bound to the lipid bilayer, and the targeting moiety is covalently bound to the linking moiety. The liposome may also include a stabilizing moiety interposed between the linking and targeting moieties, and covalently bound to both. Alternatively, the stabilizing and targeting moieties may be covalently bound to separate linking moieties, the linking moieties being electrostatically bound to the lipid bilayer.Type: ApplicationFiled: February 22, 2006Publication date: August 3, 2006Applicant: Transave, Inc.Inventors: Paul Meers, Tong Shangguan, Donna Cabral-Lilly, Patrick Ahl, Ravi Erukulla, Andrew Janoff
-
Patent number: 7060291Abstract: A liposome including a fusogenic liposome, a linking moiety and a targeting moiety. The fusogenic liposome is a lipid bilayer encapsulating contents. The linking moiety is electrostatically bound to the lipid bilayer, and the targeting moiety is covalently bound to the linking moiety. The liposome may also include a stabilizing moiety interposed between the linking and targeting moieties, and covalently bound to both. Alternatively, the stabilizing and targeting moieties may be covalently bound to separate linking moieties, the linking moieties being electrostatically bound to the lipid bilayer.Type: GrantFiled: November 17, 2000Date of Patent: June 13, 2006Assignee: Transave, Inc.Inventors: Paul R. Meers, Tong Shangguan, Donna Cabral-Lilly, Patrick Ahl, Ravi Erukulla, Andrew Janoff
-
Patent number: 6339069Abstract: Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat mammals for diseases, disorders or conditions, e.g., tumors, microbial infection and inflammations, characterized by the occurrence of peptidase-secreting cells.Type: GrantFiled: June 29, 1999Date of Patent: January 15, 2002Assignee: Elan PharmaceuticalsTechnologies, Inc.Inventors: Paul R. Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J. Craig Franklin, Ravi K. Erukulla, Donna Cabral-Lilly, Patrick L. Ahl
-
Patent number: 6143716Abstract: Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat mammals for diseases, disorders or conditions, e.g., tumors, microbial infection and inflammations, characterized by the occurrence of peptidase-secreting cells.Type: GrantFiled: October 7, 1998Date of Patent: November 7, 2000Assignee: The Liposome Company, Inc.Inventors: Paul R. Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J. Craig Franklin, Ravi K. Erukulla, Donna Cabral-Lilly
-
Patent number: 6087325Abstract: Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat mammals for diseases, disorders or conditions, e.g., tumors, microbial infection and inflammations, characterized by the occurrence of peptidase-secreting cells.Type: GrantFiled: October 15, 1997Date of Patent: July 11, 2000Assignee: The Liposome Company, Inc.Inventors: Paul R. Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J. Craig Franklin, Ravi K. Erukulla, Donna Cabral-Lilly